{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:23:12Z","timestamp":1760235792125,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113695","70113047"],"award-info":[{"award-number":["70113695","70113047"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung (IZKF), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg","award":["IZKF-J59"],"award-info":[{"award-number":["IZKF-J59"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Targeted immunotherapies have greatly changed treatment of patients with B cell malignancies. To further enhance immunotherapies, research increasingly focuses on the tumor microenvironment (TME), which differs considerably by organ site. However, immunocompetent mouse models of disease to study immunotherapies targeting human molecules within organ-specific TME are surprisingly rare. We developed a myc-driven, primary murine lymphoma model expressing a human-mouse chimeric CD22 (h\/mCD22). Stable engraftment of three distinct h\/mCD22+ lymphoma was established after subcutaneous and systemic injection. However, only systemic lymphoma showed immune infiltration that reflected human disease. In this model, myeloid cells supported lymphoma growth and showed a phenotype of myeloid-derived suppressor cells. The human CD22-targeted immunotoxin Moxetumomab was highly active against h\/mCD22+ lymphoma and similarly reduced infiltration of bone marrow and spleen of all three models up to 90-fold while efficacy against lymphoma in lymph nodes varied substantially, highlighting relevance of organ-specific TME. As in human aggressive lymphoma, anti-PD-L1 as monotherapy was not efficient. However, anti-PD-L1 enhanced efficacy of Moxetumomab suggesting potential for future clinical application. The novel model system of h\/mCD22+ lymphoma provides a unique platform to test targeted immunotherapies and may be amenable for other human B cell targets such as CD19 and CD20.<\/jats:p>","DOI":"10.3390\/ijms221910433","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T12:29:14Z","timestamp":1632832154000},"page":"10433","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments"],"prefix":"10.3390","volume":"22","author":[{"given":"Franziska","family":"Gsottberger","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Brandl","sequence":"additional","affiliation":[{"name":"Department of Biology, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-5437","authenticated-orcid":false,"given":"Kerstin","family":"Wendland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdjan","family":"Petkovic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Emmerich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0315-1229","authenticated-orcid":false,"given":"Ramona","family":"Erber","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Geppert","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Mackensen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Nitschke","sequence":"additional","affiliation":[{"name":"Department of Biology, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-5839","authenticated-orcid":false,"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation-2017.1.610","article-title":"Role of the microenvironment across histological subtypes of NHL","volume":"2017","author":"Tarte","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fimmu.2018.00070","article-title":"Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses","volume":"9","author":"Oliver","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","article-title":"A sarcoma involving the jaws in African children","volume":"46","author":"Burkitt","year":"1958","journal-title":"Br. J. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1038\/bcj.2015.56","article-title":"IL-10 induces the development of immunosuppressive CD14+HLA-DRlow\/\u2212 monocytes in B-cell non-Hodgkin lymphoma","volume":"5","author":"Xiu","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00262-017-2036-5","article-title":"Regulatory myeloid cells: An underexplored continent in B-cell lymphomas","volume":"66","author":"Roussel","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ccell.2020.04.015","article-title":"Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia","volume":"37","author":"Witkowski","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive CD14+HLA-DR(low)\/- monocytes in B-cell non-Hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hon.2019","article-title":"Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells","volume":"31","author":"Tadmor","year":"2013","journal-title":"Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27676","DOI":"10.18632\/oncotarget.8507","article-title":"Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients","volume":"7","author":"Marini","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10147-019-01520-z","article-title":"Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology","volume":"25","author":"Saito","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40259-013-0016-7","article-title":"Targeting CD22 in B-cell malignancies: Current status and clinical outlook","volume":"27","author":"Tuscano","year":"2013","journal-title":"BioDrugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"239.27","DOI":"10.4049\/jimmunol.204.Supp.239.27","article-title":"Bispecific anti-CD22 T-cell engager efficiently promotes cell-mediated cytotoxicity of lymphoma, leukemia and sarcoma targets","volume":"204","author":"Barisone","year":"2020","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab Ozogamicin: First Global Approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1002\/eji.201242629","article-title":"Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model","volume":"42","author":"Born","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/eji.202048636","article-title":"Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy","volume":"50","author":"Brandl","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2015-09-672352","article-title":"Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2015-11-684183","article-title":"B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice","volume":"127","author":"Knittel","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: Pathogenesis and classification","volume":"122","author":"Ott","year":"2013","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1084\/jem.192.8.1183","article-title":"Burkitt lymphoma in the mouse","volume":"192","author":"Kovalchuk","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1182\/blood-2019-124102","article-title":"Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed\/Refractory (r\/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1\/2 Fusion NHL-001 Global Multicenter Trial","volume":"134","author":"Casulo","year":"2019","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1158\/1078-0432.CCR-15-2500","article-title":"Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design","volume":"22","author":"Muller","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"30644","DOI":"10.18632\/oncotarget.16141","article-title":"Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies","volume":"8","author":"Stookey","year":"2017","journal-title":"Oncotarget"},{"doi-asserted-by":"crossref","unstructured":"Muller, F., Cunningham, T., Beers, R., Bera, T.K., Wayne, A.S., and Pastan, I. (2018). Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. Toxins, 10.","key":"ref_34","DOI":"10.3390\/toxins10050210"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","article-title":"Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis","volume":"22","author":"Sander","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s13577-020-00380-4","article-title":"Clinical relevance of tumor microenvironment: Immune cells, vessels, and mouse models","volume":"33","author":"Katsuta","year":"2020","journal-title":"Human Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/2159-8290.CD-17-1320","article-title":"Tissue-Specific Immunoregulation: A Call for Better Understanding of the \u201cImmunostat\u201d in the Context of Cancer","volume":"8","author":"Pao","year":"2018","journal-title":"Cancer Discovery"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.blre.2018.04.006","article-title":"Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly","volume":"32","author":"Betsch","year":"2018","journal-title":"Blood Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"E3954","DOI":"10.1073\/pnas.1616417114","article-title":"Pre\/pro-B cells generate macrophage populations during homeostasis and inflammation","volume":"114","author":"Audzevich","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","article-title":"PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation","volume":"4","author":"Frigault","year":"2020","journal-title":"Blood Adv."},{"doi-asserted-by":"crossref","unstructured":"Jiang, Q., Ghafoor, A., Mian, I., Rathkey, D., Thomas, A., Alewine, C., Sengupta, M., Ahlman, M.A., Zhang, J., and Morrow, B. (2020). Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci. Transl. Med., 12.","key":"ref_43","DOI":"10.1126\/scitranslmed.aaz7252"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity","volume":"5","author":"Leshem","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2020.00121","article-title":"Neoantigens in Hematologic Malignancies","volume":"11","author":"Biernacki","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/mt.2013.219","article-title":"Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy","volume":"22","author":"Devaud","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"54775","DOI":"10.18632\/oncotarget.18423","article-title":"Tumor location impacts immune response in mouse models of colon cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eaah6413","DOI":"10.1126\/sciimmunol.aah6413","article-title":"Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response","volume":"2","author":"Lehmann","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Lo","year":"2020","journal-title":"Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/19\/10433\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:06:04Z","timestamp":1760166364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/19\/10433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":53,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["ijms221910433"],"URL":"https:\/\/doi.org\/10.3390\/ijms221910433","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}